;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • ACT 1: Phase II data

    FirstString Research Inc., Mount Pleasant, S.C. Product: ACT 1 (Granexin gel) Business: Dermatology Molecular target: Gap junction protein alpha 1, 43kDa (GJA1) (CX43) (connexin-43) Description: Bioengineered peptide …

    Published on 10/20/2014
  • Ameluz: Preliminary Phase III data

    Biofrontera AG (Xetra:B8F), Leverkusen, Germany Product: Ameluz (BF-200 ALA) Business: Dermatology Molecular target: Not available Description: Photodynamic therapy (PDT) consisting of nanoemulsion BF-200 with 5-…

    Published on 10/20/2014
  • Autologous T cell therapy against CD19: Phase I data

    Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Product: Autologous T cell therapy against CD19 (KTE-C19) Business: Cancer Molecular target: CD19 Description: Autologous T cells genetically modified to express a …

    Published on 10/20/2014
  • CTL019: Additional Phase I/IIa data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland University of Pennsylvania, Philadelphia, Pa. Product: CTL019 (formerly CART-19) Business: Cancer Molecular target: CD19 Description: Autologous T cells loaded with a…

    Published on 10/20/2014
  • CyclASol: Phase I data

    Novaliq GmbH, Heidelberg, Germany Product: CyclASol Business: Ophthalmic Molecular target: NA Description: 0.05% clear cyclosporin solution developed using Novaliq's EyeSol semi-fluorinated alkane (SFA) drug delivery …

    Published on 10/20/2014
  • ELI-200: Clinical trial data

    Elite Pharmaceuticals Inc. (OTCBB:ELTP), Northvale, N.J. Product: ELI-200 Business: Neurology Molecular target: NA Description: Abuse deterrent-formulation of an undisclosed opioid agonist and naltrexone Indication: …

    Published on 10/20/2014
  • Enhanced TCR therapy targeting NY-ESO-1: Interim Phase I data

    Adaptimmune Ltd., Abingdon, U.K. Product: Enhanced TCR therapy targeting NY-ESO-1 Business: Cancer Molecular target: Cancer/testis antigen 1B (CTAG1B) (NY-ESO-1) Description: T cells genetically modified to express T …

    Published on 10/20/2014
  • Eylea aflibercept ophthalmic solution: Clinical trial data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Eylea aflibercept ophthalmic solution (VEGF Trap-Eye) Business: Ophthalmic Molecular target: Vascular …

    Published on 10/20/2014
  • Folate receptor alpha peptide vaccine: Phase I data

    Mayo Clinic, Rochester, Minn. Product: Folate receptor alpha peptide vaccine Business: Cancer Molecular target: Folate receptor 1 (FOLR1) (FR-alpha) Description: Vaccine comprising epitopes targeting folate receptor 1 (…

    Published on 10/20/2014
  • H7N9 VLP vaccine: Phase I/II data

    Novavax Inc. (NASDAQ:NVAX), Gaithersburg, Md. Product: H7N9 VLP vaccine Business: Infectious Molecular target: NA Description: H7N9 influenza vaccine using recombinant virus-like particle (VLP) technology Indication: …

    Published on 10/20/2014
  • MA09-hRPE cells: Phase I/II data

    Advanced Cell Technology Inc. (OTCBB:ACTC), Marlborough, Mass. Product: MA09-hRPE cells (hESC-derived hRPE cells) Business: Ophthalmic Molecular target: Not applicable Description: Human embryonic stem cell-derived …

    Published on 10/20/2014
  • MA09-hRPE cells: Phase I/II data

    Advanced Cell Technology Inc. (OTCBB:ACTC), Marlborough, Mass. Product: MA09-hRPE cells (hESC-derived hRPE cells) Business: Ophthalmic Molecular target: Not applicable Description: Human embryonic stem cell-derived …

    Published on 10/20/2014
  • Necuparanib: Phase I/II data

    Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Cambridge, Mass. Product: Necuparanib (formerly M402, M-ONC 402) Business: Cancer Molecular target: NA Description: Heparin sulfate glycosaminoglycan (HSGAG) mimetic …

    Published on 10/20/2014
  • Nuedexta dextromethorphan/quinidine: Additional Phase II data

    Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), Aliso Viejo, Calif. Product: Nuedexta dextromethorphan/quinidine (AVP-923) (formerly Neurodex) Business: Neurology Molecular target: NMDA receptor; Sigma-1 receptor Description…

    Published on 10/20/2014
  • Patisiran: Extension study interim data

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Patisiran (GZ438027, GENZ438027, ALN-TTR02) Business: Endocrine/Metabolic Molecular target: …

    Published on 10/20/2014
  • PRO 140: Phase IIb data

    CytoDyn Inc. (OTCBB:CYDY), Vancouver, Wash. Product: PRO 140 Business: Infectious Molecular target: CC chemokine receptor 5 (CCR5) (CD195) Description: Humanized mAb against CC chemokine receptor 5 (CCR5; CD195) …

    Published on 10/20/2014
  • RhGUS: Additional Phase I/II data

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Novato, Calif. Product: RhGUS (UX003) Business: Endocrine/Metabolic Molecular target: NA Description: Recombinant human glucuronidase beta (rhGUS) Indication: Treat …

    Published on 10/20/2014
  • SCIB1: Updated Phase I/II data

    Scancell Holdings plc (LSE:SCLP; Xetra:SCP), Nottingham, U.K. Product: SCIB1 Business: Cancer Molecular target: Tyrosinase-related protein 2 (TRP-2) (TYRP2) (DCT) Description: Cancer vaccine comprising the melanoma …

    Published on 10/20/2014
  • Xarelto rivaroxaban: Phase IIIb data

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Xarelto rivaroxaban (BAY 59-7939) Business: Cardiovascular Molecular target: Factor Xa Description: Direct Factor Xa …

    Published on 10/20/2014
  • ABP 501: Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Product: ABP 501 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: Biosimilar of adalimumab, a human mAb against tumor necrosis factor…

    Published on 10/13/2014
  • ACH-3102: Additional Phase II data

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: ACH-3102 Business: Infectious Molecular target: HCV NS5A protein Description: Pan-genotypic, second-generation HCV NS5A protein inhibitor …

    Published on 10/13/2014
  • Anamorelin: Phase III data

    Gen Pharmaceuticals Inc., Ankara, Turkey Helsinn Healthcare S.A., Lugano, Switzerland Specialised Therapeutics Australia Pty. Ltd., Melbourne, Australia Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: …

    Published on 10/13/2014
  • Anamorelin: Phase III data

    Gen Pharmaceuticals Inc., Ankara, Turkey Helsinn Healthcare S.A., Lugano, Switzerland Specialised Therapeutics Australia Pty. Ltd., Melbourne, Australia Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: …

    Published on 10/13/2014
  • Anthim obiltoxaximab: Phase III data

    Elusys Therapeutics Inc., Pine Brook, N.J. Product: Anthim obiltoxaximab (ETI-204) Business: Infectious Molecular target: Bacillus anthracis protective antigen Description: High-affinity humanized mAb against the …

    Published on 10/13/2014
  • Anthim obiltoxaximab: Phase III data

    Elusys Therapeutics Inc., Pine Brook, N.J. Product: Anthim obiltoxaximab (ETI-204) Business: Infectious Molecular target: Bacillus anthracis protective antigen Description: High-affinity humanized mAb against the …

    Published on 10/13/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993